TIDMABC

RNS Number : 2442T

ABCAM Plc

24 March 2016

 
 For immediate release   24 March 2016

ABCAM PLC

("Abcam" or "the Company")

Director's Dealing

Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, announces that Jim Warwick, a Director of the Company, has today transferred 3,100 Ordinary Shares of 0.2 pence each in the Company ("Ordinary Shares") for nil consideration to the Charities Aid Foundation (registered charity no. 268369).

Following this transaction, Mr Warwick's total interest in the Company has decreased by 3,100 Ordinary Shares to a total of 2,943,302 Ordinary Shares, representing approximately 1.45% of the Company's issued share capital.

For further information please contact:

 
                                       + 44 (0) 1223 
Abcam                                   696 000 
Suzanne Smith, Chief Legal Officer 
 and Company Secretary 
J.P.Morgan Cazenove - Nominated        + 44 (0) 20 
 Advisor & Corporate Broker             7742 4000 
James Mitford / Alex Bruce 
                                       + 44 (0) 20 
FTI Consulting                          3727 1000 
Ben Atwell / Brett Pollard / Natalie 
 Garland-Collins

Notes for editors:

About Abcam plc

As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated biological binders and assays to address important targets in critical biological pathways.

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health. Two-thirds of the world's 750,000 life science researchers use Abcam's affinity binders, reagents, biomarkers and assays and the Company's products are mentioned in over 20,000 of the 56,000 peer-reviewed papers published each year in the life sciences.

By actively listening to and collaborating with researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.

Abcam's ten offices are located in the world's leading life science research hubs, enabling local services and multi-language support. Founded in 1998 and headquartered in Cambridge, UK, the Company sells to more than 100 countries. Abcam was admitted to AIM in 2005 (AIM: ABC).

To find out more, please visit www.abcam.com and www.abcamplc.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSZZLFLQXFLBBQ

(END) Dow Jones Newswires

March 24, 2016 10:29 ET (14:29 GMT)

Abcam (LSE:ABC)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Abcam Charts.
Abcam (LSE:ABC)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Abcam Charts.